Login to Your Account



Zafgen Closes Series E Financing for Obesity Candidate

By Catherine Shaffer
Staff Writer

Wednesday, December 4, 2013
Zafgen Inc. will funnel its latest $45 million financing into development of its rapidly advancing obesity candidate, beloranib. The financing round included a number of new investors as well as existing investor Alta Partners, which led Zafgen’s Series D round in 2012.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription